Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital

Contraindications to interferon and ribavirin for treatment of chronic hepatitis C (CHC) are well recognized, and previous data indicated the consequent suboptimal treatment uptake.

To evaluate the treatment rate of CHC patients in a tertiary referral center in Hong Kong, and to examine the reasons for non-treatment.

A retrospective review of all referred CHC patients to the outpatient clinic was conducted. Treatment uptake rate was evaluated and patients’ sociodemographic, biochemical, and histological data were examined to identify reasons for treatment decision.

CHC patients (303) were assessed for antiviral therapy from 2000 to 2009. Of the patients, 138 (45.5%) did not receive antiviral therapy. Reasons for non-treatment were as follows: 31.9% declined treatment, 18.8% had decompensated cirrhosis, 12.3% were considered too elderly, 17.4% had too mild liver disease, 7.2% had psychiatric history, 7.2% had significant comorbidities, and 2.9% had ongoing alcohol or substance abuse. Independent factors associated with non-treatment were older age (adjusted odds ratio [aOR] 1.05, 95% confidence interval [CI] 1.03–1.08, p < 0.001), significant comorbidities (aOR 2.53, 95% CI 1.34–4.78, p = 0.004), psychiatric history (aOR 6.04, 95% CI 2.14–17.02, p < 0.001), mild liver disease (aOR 7.72, 95% CI 3.86–15.44, p < 0.001) and decompensated cirrhosis (aOR 9.42, 95% CI 2.57–34.50, p < 0.001).

Current treatment uptake for CHC patients was suboptimal, as a large proportion of patients were either reluctant for treatment or not suitable for the current antiviral therapy. Multidisciplinary interventions are needed in the short term while alternative antiviral therapy is desired in the long term to overcome barriers to treatment.